DRUG SURVIVAL OF DIFFERENT BIOLOGICS IN PSORIATIC PATIENTS - EVIDENCE SYNTHESIS AND HISTORICAL COHORT STUDY

Abstract

Biologic therapies have revolutionized the treatment of psoriasis, providing high levels of efficacy and safety. However, the choice of the appropriate therapy for each patient remains a challenge. The primary objective is to evaluate the survival rates and the all-cause discontinuation hazard ratio compared to adalimumab in treating psoriasis in all treatment series. This study is a retrospective survival analysis conducted at Hamad Medical Corporation in Qatar using the electronic medical records to collect data for patients who received biologics between Jan 2016 and Jan 2023. To compare the survival rates and all-cause discontinuation of biologics, patients with a confirmed dispensing of adalimumab, etanercept, guselkumab, infliximab, ixekizumab, secukinumab, or ustekinumab for psoriatic diagnosis. For the total treatment series model, the Kaplan- Meier survival curve was used to estimate the survival function for each biologic. In conclusion, this study has provided valuable insights into the comparative effectiveness of different biologic treatments for biologic-naive patients with psoriasis. Our findings revealed significant differences in treatment outcomes among various biologics, with some agents demonstrating superior effectiveness compared to adalimumab.